CD274 and neoplasm: Recently, the US Food and Drug Administration approved use of adjuvant (anti-PD-L1) immunotherapy following resection and platinum-based chemotherapy for patients with stage II-IIIA NSCLC (and whose tumors have PD-L1 expression on ≥1% of tumor cells).21